LIES: How the All-In Podcast Lied Again [Cancer Vaccine].
Overall Thesis
Meet Kevin critiques David Friedberg's misleading claims about Moderna and Merck's cancer vaccine breakthrough, arguing Friedberg fundamentally misunderstood the science and regulatory value of the therapy.
Narratives
Kevin defends Moderna's Interpath 001 phase 3 melanoma therapy (developed with Merck) as a genuine scientific breakthrough, arguing it fundamentally differs from cheaper non-FDA compounded neoantigen peptide treatments because it activates a much broader immune response. He explicitly says he is not telling viewers to invest and discloses only a 'very, very teeny bit' of long exposure to the stock.
Key Arguments
- The mRNA nanoparticle process trains dendritic cells to activate both CD4+ ('town guard') and CD8+ ('hunter') immune cells, unlike simple peptide injections which only activate the more limited external-threat response
- Moderna's therapy targets about 32 tumor mutations simultaneously, making it resilient even if the cancer mutates in most of those spots
- AI dramatically sped up identification of viable tumor mutations for targeting, from ~60 days per mutation to hours
- Phase 3 trial data showed at least 59% reduction in cancer metastasis/recurrence
Kevin frames Merck as Moderna's partner in the Interpath 001 phase 3 melanoma therapy trial and defends the legitimacy and value of the treatment against David Friedberg's dismissal on the All-In podcast. He does not make any specific stock price claims and explicitly states he is not offering investment advice.
Key Arguments
- Merck and Moderna jointly ran the Interpath 001 phase 3 trial that met its primary endpoint of reducing melanoma recurrence
- The partnership's approach could extend to other solid tumor cancers beyond melanoma
Kevin mentions BioNTech as a competitor pursuing a similar mRNA neoantigen cancer therapy approach, though it targets fewer mutations (18-20 versus Moderna's 32) and is only in phase two trials, making it 'the second horse in this race.' No price prediction is made.
Key Arguments
- BioNTech's therapy targets about 18-20 mutations compared to Moderna's roughly 32
- BioNTech is behind Moderna, still in phase two trials versus Moderna's phase three
Hedges & Caveats
- Kevin emphasizes this is educational content to correct misinformation, not to 'dunk on' the All-In podcast
- Kevin notes the trial is still ongoing and results are not yet finalized
- Kevin acknowledges this is about basic science, not political commentary on public funding